Close
More
 
back_btn_arrow   Go back
Sign up or login to continue
New to Univadis?
Univadis is a free service for United States Healthcare Professionals.
*Please fill in all required fields.
By clicking "Sign up", I agree to the Terms of Use and Privacy Policy. and attest I am a healthcare professional.
Existing Univadis member:
Sign up or login to continue
Make more time for the moments that matter. Get expertly-curated updates and medical education, instantly.
New to Univadis?
Simply enter a password to join for free, if the information below is correct.
 
*Please enter a valid email address and password.
By clicking "Sign up", I agree to the Terms of Use and Privacy Policy. and attest I am a healthcare professional.
Forgot your password?  Reset now
Existing Univadis member:
Please login to continue
Welcome! Great to have you back.
*Your email address or password is incorrect.
Forgot your password?  Reset now
Reset your password
Please enter your email address, and we will send you a link to reset your password.
*Please enter a valid email address.

is already registered on Univadis

Is this you? Enter your password to continue.
The password you entered is incorrect. Please try again or choose a different option.
Forgot your password?  Reset now
Need more help? Please contact Member Service at support@univadis.com

is already registered on Univadis

Need more help? Please contact Member Service at support@univadis.com
Instructions to create a new password have been sent to the following email address:

For further assistance, please Contact Member Support
Thanks for Registering.
BreadCrumbsIncluded hideAllBreadCrumbs
World Conference on Lung Cancer
Barcelona, Spain, September 7-10, 2019
News Coverage
Essential conference news
Existing information on clinical trials is not always accessible or understandable. Patients’ lack of knowledge and awareness leads to trials...
September 13, 2019
According to a pooled analysis of CheckMate 017 and 057 studies, nivolumab leads to better survival outcomes and is well tolerated in the long-term.
September 13, 2019
Immunotherapy has a key role in lung cancer treatment, but efforts are needed to improve treatment schedules and to select the right drug for the...
September 13, 2019
New KEYNOTE-021 and KEYNOTE-189 data shows no association of tissue tumour mutational burden with clinical outcomes of pembrolizumab plus chemotherapy
September 13, 2019
KEYNOTE-042 China study showed significative improvements in survival with first-line immunotherapy compared to chemotherapy, consistent with...
September 12, 2019
Pathological analysis and molecular testing require sufficient amounts of high-quality samples; cryobiopsy is a new tool to obtain optimal tumour...
September 12, 2019
Immune-related adverse events occur early in patients with SCLC treated with immune checkpoint inhibitors and seem to correlate with biomarkers of...
September 12, 2019
According to the CASPIAN study, adding immunotherapy to the standard chemotherapy as first-line treatment in small-cell lung cancer leads to a 27%...
September 12, 2019
Checkmate 817 trial showed that patients with comorbidities and impaired performance status could benefit from first-line treatment with nivolumab...
September 11, 2019
Results of bioMILD trial indicate that longer LDCT screening intervals are feasible and safe in selected high-risk subjects
September 11, 2019
Data from the VIOLET trial support the use of this minimally invasive surgical technique in early stage lung cancer
September 11, 2019
Treatment is effective in terms of local control of the disease, without inducing severe toxicity according to a retrospective review
September 11, 2019
IASLC urges healthcare providers to assist their cancer patients with smoking cessation, a decision with huge consequences on patient health and...
September 10, 2019
According to a phase 1 trial, AMG 510 molecule is well tolerated and shows anti-tumour activity in Non-Small Cell Lung Cancers harbouring the KRAS...
September 10, 2019
Lung Cancer specialists presented thousands of studies at this year’s WCLC meeting. Univadis journalists chose the most clinically relevant ones and summarized them in our easy-to-scan bullet-point format.

Univadis is a free, time-saving medical news & education community designed exclusively for healthcare professionals. Unique executive summaries tame the onslaught of medical literature and keep clinicians up to date in just a few minutes per day. Concise, interactive educational presentations from our experts help clinicians stay on top of practice-changing research and trends, and collaborate with colleagues at any time, on any device.

Aptus Health does not endorse and is not responsible for the accuracy of the content, or for practices or standards of non-Aptus Health sources.

Copyright © 2019 Aptus Health, Inc. All rights reserved. Version 2.14.541.9

Mobile App

Contact Us

(888) 729-4546
Monday - Friday 8am to 7pm ET

support@univadis.com